Further studies are needed to precisely characterize the MAPK optimum, explore the therapeutic potential of eIF4F inhibitors, and unravel the compensatory mechanisms that sustain melanoma cell survival in the context of reduced protein synthesis. This evidence concerns the gene EIF4G1 and melanoma.